CFO SpotlightsCareers of chief financial officers, from the filings. Records as of October 28, 2026
  1. CFO Spotlights
  2. Profiles
  3. Matthew Szot

Profile

Matthew Szot

Chief Financial Officer, Stark Focus Group, Inc.

In the seat. First published here October 28, 2026; built from records as of October 28, 2026.

Matthew Szot has been Chief Financial Officer of Stark Focus Group, Inc. since October 8, 2026, according to the company's filing of September 25, 2026.2

The filing gives Matthew Szot's previous role as Chief Financial Officer at Cadrenal Therapeutics, Inc.2 Matthew Szot joined from outside Stark Focus Group, Inc., by the record's reading of the filing.2 The filing shows an earlier chief financial officer seat, so this is not Matthew Szot's first.2

The record also places Matthew Szot in the finance seat at one other company: Cadrenal Therapeutics, Inc. (a later filing names a successor). Each is set out below, filing by filing.

Seats

2 seats in the record

CompanyTitle as filedStandingFilings
Stark Focus Group, Inc.Chief Financial OfficerIn the seat1
Cadrenal Therapeutics, Inc. (CVKD)
Pharmaceutical Preparations
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)A later filing names a successor
Quang X. Pham, filed June 3, 2026 (filing)
1

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

  1. October 8, 2026effective

    Stark Focus Group, Inc. appointed Matthew Szot as Chief Financial Officer, effective October 8, 2026. Profile of John Lipman.

    On September 21, 2026, the Board of Directors (the “ Board ”) of Stark Focus Group, Inc. (the “ Company ”) unanimously approved the appointment of Matthew Szot to be the Company’s new Chief Financial Officer, effective on […]

    [2] Filing by Stark Focus Group, Inc., filed with the SEC on September 25, 2026. Read the filing. The record at CFO Tribune.

  2. March 31, 202610-K filed

    Matthew Szot signed the annual report of Cadrenal Therapeutics, Inc. on Form 10-K as Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer), filed March 31, 2026.

    /s/ Matthew Szot Chief Financial Officer (Principal Financial Officer March 31, 2026 Matthew Szot and Principal Accounting Officer)

    [1] Annual report on Form 10-K by Cadrenal Therapeutics, Inc., filed with the SEC on March 31, 2026. Read the filing. The record at CFO Tribune.

Sources

Sources

  1. Annual report on Form 10-K, Cadrenal Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed March 31, 2026. sec.gov; record.
  2. Current report filed with the SEC, Stark Focus Group, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed September 25, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Matthew Szot wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.